Last month FDA granted permission for “expanded access” to an experimental medicine for Ebola virus infection. The drug, currently designated TKM-Ebola, has barely begun to be tested for safety and efficacy and is available in extremely limited quantities. It will be administered to patients with confirmed or suspected Ebola infections but not as part of a clinical trial.
Congress and the scientific community need to review and revise the nation’s research priorities. We are wasting money on trivial or poorly-conceived projects while life-threatening illnesses are shortchanged.
Remember that 2008 campaign promise touted by then-candidate Obama — that his health care law would reduce the cost of premiums by $2,500 by 2014? As we have noted, he was quickly called out by fact checkers for making a dubious claim based on shaky assumptions.
The Working Group on Health Care Policy devises public policies that enable more Americans to get better value for their health care dollar and foster appropriate innovations that will extend and improve life.